- Conditions
- Chronic Hepatitis C Virus Infection
- Interventions
- ABT-333, Placebo for ABT-333, Pegylated interferon, Ribavirin
- Drug · Other
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 7
- States / cities
- Anaheim, California • Los Angeles, California • Orlando, Florida + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 697–720
of 901
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hypercholesterolemia, Heterozygous Familial
- Interventions
- mipomersen sodium 200 mg, Placebo, mipomersen sodium 70 mg
- Drug
- Lead sponsor
- Kastle Therapeutics, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 309 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 20
- States / cities
- Mission Viejo, California • Aurora, Colorado • Cooper City, Florida + 17 more
- Conditions
- HIV-1-Infection
- Interventions
- Lepetegravir, Lenacapavir pacfosacil, Placebo to Match BVY, Bictegravir/emtricitabine/tenofovir alafenamide, Lepetegravir/Lenacapavir pacfosacil FDC, Placebo to Match GS1720/GS-4182 FDC
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 675 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 30 more
- Conditions
- Membranous Nephropathy, Nephrotic Syndrome
- Interventions
- Belimumab, Placebo for Belimumab, Rituximab
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • San Francisco, California + 17 more
- Conditions
- Gestational Diabetes, Glucose Intolerance
- Interventions
- Non-intervention group, Face to face, Telehelath Group
- Behavioral
- Lead sponsor
- Pennington Biomedical Research Center
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- Baton Rouge, Louisiana
- Conditions
- Healthy, Dermatitis, Atopic
- Interventions
- LY3844583, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Tourette's Disorder
- Interventions
- Aripiprazole, Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 7 Years to 17 Years
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 13
- States / cities
- Dothan, Alabama • San Francisco, California • Gainesville, Florida + 9 more
- Conditions
- Hepatitis C
- Interventions
- CTS-1027, pegylated interferon, Ribavirin, Placebo
- Drug
- Lead sponsor
- Conatus Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 45
- States / cities
- Birmingham, Alabama • Coronado, California • La Jolla, California + 33 more
- Conditions
- Non-Small-Cell Lung Carcinoma
- Interventions
- TG4010, placebo
- Biological · Drug
- Lead sponsor
- Transgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 12
- States / cities
- Scottsdale, Arizona • Topeka, Kansas • Louisville, Kentucky + 9 more
- Conditions
- Type II Diabetes Mellitus
- Interventions
- GL0034 Dose Level 1, GL0034 Dose Level 2, GL0034 Dose Level 3, GL0034 Dose Level 4, GL0034 Dose Level 5, GL0034 Dose Level 6, Placebo
- Drug · Other
- Lead sponsor
- Sun Pharmaceutical Industries Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 285 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 9
- States / cities
- Little Rock, Arkansas • Hialeah Gardens, Florida • Lakeland, Florida + 5 more
- Conditions
- Overweight, Obesity
- Interventions
- Semaglutide, Placebo (semaglutide)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 17,604 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 205
- States / cities
- Birmingham, Alabama • Montgomery, Alabama • Glendale, Arizona + 163 more
- Conditions
- Healthy
- Interventions
- LY3463251, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 118 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Daytona Beach, Florida
- Conditions
- Menopause, Obesity, Abdominal, Aging, Weight Gain
- Interventions
- GnRH antagonist, Estrogen Product, Placebo estradiol, Placebo GnRH antagonist
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 40 Years to 65 Years · Female only
- Enrollment
- 57 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Obesity
- Interventions
- Semaglutide 2.4 mg and NNC0165-1875 2.0 mg, Semaglutide 2.4 mg and placebo 2.0 mg, Semaglutide 2.4 mg and NNC0165-1875 1.0 mg, Semaglutide 2.4 mg and placebo 1.0 mg
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Anaheim, California • Chula Vista, California + 22 more
- Conditions
- Dermatitis, Atopic
- Interventions
- Placebo, Bermekimab, Dupilumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 18
- States / cities
- Los Angeles, California • Santa Ana, California • Orange Park, Florida + 15 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Zenagamtide, Semaglutide, Placebo zenagamtide, Placebo semaglutide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,060 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 41
- States / cities
- La Jolla, California • Lancaster, California • Lincoln, California + 34 more
- Conditions
- Multiple Sclerosis
- Interventions
- Fingolimod 1.25 mg, Fingolimod 0.5 mg, Interferon β-1a 30 µg
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 1,292 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 35
- States / cities
- Cullman, Alabama • Phoenix, Arizona • Oceanside, California + 31 more
- Conditions
- Tourette's Disorder
- Interventions
- Aripiprazole, Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 7 Years to 17 Years
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 20
- States / cities
- Little Rock, Arkansas • Sacramento, California • Santa Ana, California + 16 more
- Conditions
- Metabolism and Nutrition Disorder, Obesity
- Interventions
- NNC0194-0499, Placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 22 Years to 55 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Obesity
- Interventions
- JNJ-64565111 Dose Level 1, JNJ-64565111 Dose Level 2, JNJ-64565111 Dose Level 3, Liraglutide, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 474 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Walnut Creek, California • Jacksonville, Florida + 14 more
- Conditions
- Gout
- Interventions
- Rilonacept, Placebo
- Biological · Other
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1,315 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 77
- States / cities
- Alabaster, Alabama • Mesa, Arizona • Burbank, California + 74 more
- Conditions
- Non-Alcoholic Fatty Liver Disease
- Interventions
- ALT-801, Placebo
- Drug · Other
- Lead sponsor
- Altimmune, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 15
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Montclair, California + 9 more
- Conditions
- Cocaine Use Disorder, HIV
- Interventions
- Semaglutide, Placebo
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Baltimore, Maryland
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Insulin icodec, Placebo insulin icodec, Insulin degludec, Placebo insulin degludec
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 588 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 94
- States / cities
- Birmingham, Alabama • Guntersville, Alabama • Little Rock, Arkansas + 81 more